Pseudoxanthoma Elasticum
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Daiichi SankyoChina - Shanghai
2 programsNon InterventionalN/A1 trial
DS-1211bPHASE_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Daiichi SankyoDS-1211b
Daiichi SankyoNon Interventional
Clinical Trials (2)
Total enrollment: 113 patients across 2 trials
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Start: Oct 2022Est. completion: Nov 202365 patients
Phase 2Completed
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Start: Aug 2021Est. completion: Aug 202248 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.